Η βιοτρομοκρατία και η σύγχρονη αναγκαιότητα της βιοάμυνας

PDF (ελληνικά)
Veröffentlicht: Oct 7, 2021
DOI: https://doi.org/10.12681/bioeth.28157
Natalia Amasiadi
Abstract

Εισαγωγή: Η επιστημονική πρόοδος κατέστησε τον κίνδυνο ενός απρόσμενου βιοτρομοκρατικού επεισοδίου απολύτως υπαρκτό. Συνεπώς, η δημιουργία μιας ισχυρής «ασπίδας» προστασίας, η οποία είναι κοινώς γνωστή ως «βιοασφάλεια» και κατ’ επέκταση, ως «βιοάμυνα» αποτελεί μια σύγχρονη ανάγκη, συνοδευόμενη με ηθικά διλήμματα και πλείστους προβληματισμούς.

Μέθοδοι/Δεδομένα: Το ξέσπασμα της COVID–19 απέδειξε αναπόδραστα την αναγκαιότητα και η σημασία της δημιουργίας μιας ισχυρής βιοάμυνας. Τα συστήματα βιοάμυνας, τα επιτελικά σχέδια εκτάκτου ανάγκης, το risk communication, οι επαρκείς υποδομές, το εξειδικευμένο προσωπικό, τα ενδεδειγμένα μέτρα ατομικής προστασίας, οι διασφαλισμένοι οικονομικοί πόροι, η ρεαλιστική εκτίμηση κινδύνου και κυρίως τα μέσα πρόληψης, δηλαδή η αποφυγή και αποτροπή των καταστάσεων αυτών πριν εξαπλωθούν, αποτελούν πρωταρχικούς στόχους.

Αποτελέσματα: Η λεπτομερής καταγραφή των συναφών δεδομένων, θα μας βοηθήσουν να κατανοήσουμε με ένα καλύτερο τρόπο την αποτελεσματική δόμηση ισχυρών συστημάτων βιοάμυνας, και θα αναδείξουν τα ζητήματα βιοηθικής και θεσμοθέτησης, πιθανώς σε παγκόσμιο επίπεδο, με σκοπό τη δημιουργία εφοδίων και αποτελεσματικών μεθόδων αντιμετώπισης της βιοτρομοκρατίας. 

Σύνοψη/Συζήτηση: Πρωταρχικός σκοπός αναδεικνύεται η κατανόηση της σημαντικότητας λήψης προστατευτικών μέτρων ενάντια στη βιοτρομοκρατία και η δημιουργία ισχυρών συστημάτων βιοάμυνας, τα οποία θα χαίρουν ευρείας επιστημονικής αποδοχής και θα στηρίζονται στην επιστημονική έρευνα και εποπτεία του φαινομένου. Τέλος, ως σημαντικό αποτρεπτικό μέσο, κρίνεται η θεσμοθέτηση κανόνων πρόληψης και αποφυγής φαινομένων βιοτρομοκρατίας, σε εθνικό αλλά και σε διεθνές επίπεδο.

Article Details
  • Rubrik
  • Original Articles
Creative-Commons-Lizenz
Dieses Werk steht unter der Lizenz Creative Commons Namensnennung 4.0 International.

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution  CC BY 4.0 License, which allows for immediate free access to the work and permits any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose. Appropriate credit must be given by citing the author(s) and the original publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g. post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

We encourage authors to deposit their articles, as well as data underlying the publications, in institutional and/or other appropriate subject repositories.

Bioethica permits and encourages authors to archive the final publication pdf  in institutional (e.g. the repository of the National Hellenic Research Foundation) or other appropriate subject repositories (e.g. SSOAR repository for social sciences),  in compliance with institutional and/or funder open access policies, after publication in the BIOETHICA. Authors must provide bibliographic details that credit publication in the journal, as well as related funding details (when applicable).

Lists of institutional and other subject-based academic open access repositories can be found listed by country at the registry http://opendoar.org/countrylist.php   

If your institution does not possess a repository you may deposit a copy of your paper at no cost with www.zenodo.org , the repository supported for open access research in the EU by the European Commission, through the project OpenAIRE (www.openaire.eu )

Downloads
Keine Nutzungsdaten vorhanden.
Literaturhinweise
Berger KM. Emerging and Enabling Technologies in Biodefense. Defense Against Biological Attacks 2019, 1: 253–281.
Radosavljević V, Jakovljević B. Bioterrorism-types of epidemics, new epidemiological paradigm, and levels of prevention. Public Health 2007, 121: 549-557.
Chehrehgosha M. The Unpreparedness of the Healthcare System for the Management of COVID-19 Pandemic Leading to the Mistreatment of the Elderly: A Newly Emerging Moral Dilemma. J Nutr Health Aging 2020, 24: 973-974.
Robert R, Kentish-Barnes N, Boyer A. et al. Ethical dilemmas due to the Covid-19 pandemic. Ann. Intensive Care 2020, 10: 1-9.
Mehta A, Quinn TC. Addressing Future Epidemics: Historical Human Rights Lessons from the AIDS Pandemic. Pathog Immun 2016, 1: 1-11.
Riedel S. Biological warfare and bioterrorism: a historical review. Proc (Bayl Univ Med Cent) 2004, 17: 400-406.
Wallin A, Luksiene Z, Zagminas K, Surkiene G. Public health, and bioterrorism: renewed threat of anthrax and smallpox. Medicina (Kaunas) 2007 43: 278-284.
Frischknecht F. The history of biological warfare. Human experimentation, modern nightmares, and lone madmen in the twentieth century. EMBO Rep 2003, 4: 47-52.
Hope-Simpson RE. The method of transmission of epidemic influenza: further evidence from archival mortality data. J Hyg 1986, 96: 353-75.
Tian D, Zheng T. Comparison and analysis of biological agent category lists based on biosafety and biodefense. PLoS One 2014, 9: 1-6.
Kearney A, Pettit C. Introduction to Biological Agents and Pandemics. Ciottone's Disaster Medicine 2016: 696–598.
Daly T, Dickson K. Biological hazards. Nurs Stand1998, 13: 43-49.
Ahmad T, Haroon, Dhama K, Sharun K, Khan FM, Ahmed I, Tiwari R, Musa TH, Khan M, Bonilla-Aldana DK, J Rodriguez-Morales A, Hui J. Biosafety and biosecurity approaches to restrain/contain and counter SARS-CoV-2/COVID-19 pandemic: a rapid-review. Turk J Biol 2020, 44: 132-145.
Wynia MK, Gostin LO. Ethical challenges in preparing for bioterrorism: barriers within the health care system. Am J Public Health 2004, 94: 1096-1102.
Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC, Memish Z, Oh MD, Sall AA, Schuchat A, Ungchusak K, Wieler LH. WHO Strategic and Technical Advisory Group for Infectious Hazards. COVID-19: towards controlling of a pandemic. Lancet, 395: 1015-1018.
Nicola M, O'Neill N, Sohrabi C, Khan M, Agha M, Agha R. Evidence based management guideline for the COVID-19 pandemic - Review article. Int J Surg 2020, 77: 206-216.
Artenstein AW. Bioterrorism and Biodefense. Infectious Diseases. 2017: 670–679.
Nuzzo JB. Improving Biosurveillance Systems to Enable Situational Awareness During Public Health Emergencies. Health Secur 2017, 15: 17-19.
Nayahangan LJ, Konge L, Russell L, Andersen S. Training, and education of healthcare workers during viral epidemics: a systematic review. BMJ Open 2021, 11: 1-9.
Lele DV. Risk assessment: A neglected tool for health, safety, and environment management. Indian J Occup Environ Med 2012, 16: 57-58.
Coelho AC, García Díez J. Biological Risks and Laboratory-Acquired Infections: A Reality That Cannot be Ignored in Health Biotechnology. Front Bioeng Biotechnol 2015, 3: 1-10.
Herron JBT, Hay-David AGC, Gilliam AD, Brennan PA. Personal protective equipment and Covid 19- a risk to healthcare staff? Br J Oral Maxillofac Surg 2020, 58: 500-502.
Agarwal A, Agarwal S, Motiani P. Difficulties Encountered While Using PPE Kits and How to Overcome Them: An Indian Perspective. Cureus 2020, 12: 1-10.
Shrivastava SR, Shrivastava PS, Ramasamy J. Risk Communication: An Integral Element in Public Health Emergencies. Int J Prev Med 2016, 7: 12.
Opel DJ, Lo B, Peek ME. Addressing Mistrust About COVID-19 Vaccines Among Patients of Color. Ann Intern Med 2021, 174: 698-700.
Occupational Safety and Health Administration. Personal Protective Equipment. Available at: https://www.osha.gov/ Accessed 11.3.2020.
Εθνικός Οργανισμός Δημόσιας Υγείας. Εφαρμογή μέτρων ατομικής προστασίας. Διαθέσιμο από: https://eody.gov.gr/Accessed 27.11.2020.
Consolidated Sterilizer Systems. Do You Know the Difference in Laboratory Biosafety Levels 1, 2, 3 & 4? Available at: https://consteril.com/biosafety-levels-difference/ Accessed 2.12.2020.
Center of Disease and Control Prevention. Recognizing the Biosafety Levels. Available at: https://www.cdc.gov/Accessed 2.12.2020.
Gupta, A., Sterilization for Beginners: The Inner Workings of a Laboratory Autoclave. Consolidated Sterilizer Systems. Available at: https://consteril.com/how-does-a-laboratory-autoclave-work/ Accessed 3.12.2020.
Janosko K, Holbrook MR, Adams R, Barr J, Bollinger L, Newton JT, Ntiforo C, Coe L, Wada J, Pusl D, Jahrling PB, Kuhn JH, Lackemeyer MG. Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 1. Biosafety Level 4 Suit Laboratory Suite Entry and Exit Procedures. J Vis Exp 2016, 116: 1-6.
Memarzadeh, F., 2010. Health and safety risk assessment methodology to calculate reverse airflow tolerance in a biosafety level 3 (BSL-3) or airborne infection isolation room (AII) environment. Int. J. Risk Assessment and Management, Vol. 14: 1-2.
Homer LC, Alderman TS, Blair HA, Brocard AS, Broussard EE, Ellis RP, Frerotte J, Low EW, McCarthy TR, McCormick JM, Newton JM, Rogers FC, Schlimgen R, Stabenow JM, Stedman D, Warfield C, Ntiforo CA, Whetstone CT, Zimmerman D, Barkley E. Guidelines for Biosafety Training Programs for Workers Assigned to BSL-3 Research Laboratories. Biosecur Bioterror 2013, 11: 10-9.
Nisii C, Castilletti C, Raoul H, Hewson R, Brown D, Gopal R, Eickmann M, Gunther S, Mirazimi A, Koivula T, Feldmann H, Di Caro A, Capobianchi MR, Ippolito G. Biosafety Level-4 laboratories in Europe: opportunities for public health, diagnostics, and research. PLoS Pathog 2013, 9: 1-4.
Rasmussen L, Tigabu B, White EL, Bostwick R, Tower N, Bukreyev A, Rockx B, LeDuc JW, Noah JW. Adapting high-throughput screening methods and assays for biocontainment laboratories. Assay Drug Dev Technol 2015, 13: 44-54.
Tarricone R, Rognoni C. What can health systems learn from COVID-19? European Heart Journal Supplements 2020, 22: 4-8.
Osterholm MT. Global Health Security—An Unfinished Journey. Emerg Infect Dis 2017, 23: 225–227.
Wieczorek WF, Delmerico AM. Geographic Information Systems. Comput Stat 2009, 1: 167-186.
Landau S. Transactional information is remarkably revelatory. Proc Natl Acad Sci U S A 2016, 113: 5467-9.
Hand DJ. Aspects of Data Ethics in a Changing World: Where Are We Now? Big Data 2018, 6: 176-190.
Shi X, Wu X. An overview of human genetic privacy. Ann N Y Acad Sci 2017, 1387: 161-172.
Sass HM. The Journal of Medicine and Philosophy: A Forum for Bioethics and Philosophy of Medicine 1998, 23: 227–233.
Williams M, Armstrong L, Sizemore DC. Biologic, Chemical, and Radiation Terrorism Review. StatPearls. 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493217/ Accessed 3.07.2021.
Pinto VN. Bioterrorism: Health sector alertness. J Nat Sci Biol Med 2013, 4: 24-28.
Parida MM, Dash PK, Shukla J. Advance detection technologies for select biothreat agents. Handbook on Biological Warfare Preparedness, 2020: 83–102.
Prakash N, Sharada P, Pradeep G. Bioterrorism: Challenges and considerations. J Forensic Dent Sci 2010, 2: 59-62.
Cooper GF, Villamarin R, Rich Tsui FC, Millett N, Espino JU, Wagner MM. A method for detecting and characterizing outbreaks of infectious disease from clinical reports. J Biomed Inform 2015, 53: 15-26.
World Health Organization. Managing Epidemics. Key facts about Major Deadly Disease. Available at: https://www.who.int/ Accessed 5.12.2020.
Narain JP, Dawa N, Bhatia R. Health System Response to COVID-19 and Future Pandemics. Journal of Health Management 2020, 22: 138-145.
Kieny MP, Bekedam H, Dovlo D, Fitzgerald J, Habicht J, Harrison G, Kluge H, Lin V, Menabde N, Mirza Z, Siddiqi S, Travis P. Strengthening health systems for universal health coverage and sustainable development. Bull World Health Organ 2017, 95: 537-539.
Chow C, Shahdadpuri R, Kai-Qian K, Hwee CY. The Next Pandemic: Supporting COVID-19 Frontline Doctors Through Film Discussion. J Med Humanit 2020, 41: 585-595.
Wojda TR, Valenza PL, Cornejo K, McGinley T, Galwankar SC, Kelkar D, Sharpe RP, Papadimos TJ, Stawicki SP. The Ebola Outbreak of 2014-2015: From Coordinated Multilateral Action to Effective Disease Containment, Vaccine Development, and Beyond. J Glob Infect Dis 2015, 7: 127-38.
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, Smoot J, Gregg AC, Daniels AD, Jervey S, Albaiu D. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci 2020, 6: 315-331.
Welby-Everard P, Quantick O, Green A. Emergency preparedness, resilience, and response to a biological outbreak. BMJ Mil Health 2020, 166: 37-41.
Zhu Y, Li J, Pang Z. Recent insights for the emerging COVID-19: Drug discovery, therapeutic options, and vaccine development. Asian Journal of Pharmaceutical Sciences 2021, 16: 4-23.
Sharma D, Mishra A, Newaskar V, Khasgiwala A. Bioterrorism: Law Enforcement, Public Health & Role of Oral and Maxillofacial Surgeon in Emergency Preparedness. J Maxillofac Oral Surg 2016, 15: 137-143.